(6-氯-咪唑并[2,1-b]噻唑-5-基)-甲醇 | 24918-13-6

• 分子结构分类: 有机化合物 - 有机卤素化合物 - 芳基卤化物
• 中文名称: (6-氯-咪唑并[2,1-b]噻唑-5-基)-甲醇
• 中文别名: (6-氯咪唑并[2,1-B]噻唑-5-基)甲醇
• 英文名称: 5-hydroxymethyl-6-chloroimidazo<2,1-b>thiazole
• 英文别名: 5-idrossimetil-6-cloroimidazo<2,1-b>tiazolo；6-chloro-imidazo[2,1-b]thiazole-5-methanol；{6-chloroimidazo[2,1-b][1,3]thiazol-5-yl}methanol；6-Chlor-5-hydroxymethyl-imidazo<2,1-b>thiazol；(6-Chloroimidazo[2,1-b][1,3]thiazol-5-yl)methanol
• CAS: 24918-13-6
• 化学式: C₆H₅ClN₂OS
• mdl: MFCD02253174
• 分子量: 188.638
• InChiKey: PWHRIJYPBNUZLZ-UHFFFAOYSA-N

物化性质

• 熔点：
  168-170°

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.166
• 拓扑面积：
  65.8
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2934100090

反应信息

• 作为反应物：
  描述：

  (6-氯-咪唑并[2,1-b]噻唑-5-基)-甲醇 在 五氯化磷 作用下， 以 甲苯 为溶剂， 反应 2.0h， 生成 6-Chloro-5-(chloromethyl)imidazo[2,1-b][1,3]thiazole
  参考文献：
  名称：

  Andreani, Aldo; Leoni, Alberto; Locatelli, Alessandra, Arzneimittel-Forschung/Drug Research, 2000, vol. 50, # 6, p. 550 - 553

  摘要：

  DOI：
• 作为产物：
  描述：

  6-氯咪唑并[2,1-b][1,3]噻唑-5-甲醛 在 sodium tetrahydroborate 作用下， 以 甲醇 为溶剂， 生成 (6-氯-咪唑并[2,1-b]噻唑-5-基)-甲醇
  参考文献：
  名称：

  Andreani, A.; Bonazzi, D.; Rambaldi, M., Farmaco, Edizione Scientifica, 1980, vol. 35, # 11, p. 896 - 901

  摘要：

  DOI：

文献信息

• PYRIMIDINES AS NOVEL THERAPEUTIC AGENTS
  申请人：Université Laval

  公开号：US20150225423A1

  公开（公告）日：2015-08-13

  The present invention features compounds having the Formula (Ia) and (Ib) (e.g., a compound of any of Formulas ((Ia-2)-(Ia-21)), including other tautomers, stereoisomers, E/Z stereoisomers, prodrugs, pharmaceutically acceptable salts, and compositions thereof. The invention also features methods for treating or preventing pain (e.g., neuropathic pain), inflammation, or epilepsy in a patient by administering an effective amount of a compound of Formula (Ia) or (Ib). The invention also features a method for treating or preventing pain (e.g., neuropathic pain), inflammation, or epilepsy in a patient that includes administering to a patient in need thereof an effective amount of a compound of Formula (IIa) or (IIb) (e.g., a compound of any of Formulas ((IIa-2)-(IIa-6)). The compounds described herein (e.g., a compound of Formulas (Ia), (Ib), (IIa), or (IIb)) can also be used as anticonvulsants.

  本发明涉及具有式(Ia)和(Ib)的化合物(例如，任何公式((Ia-2)-(Ia-21))的化合物，包括其他互变异构体、立体异构体、E/Z立体异构体、前药、药学上可接受的盐及其组合物。本发明还涉及通过给患者施用式(Ia)或(Ib)的化合物的有效量来治疗或预防疼痛(例如，神经痛)、炎症或癫痫的方法。本发明还涉及一种治疗或预防疼痛(例如，神经痛)、炎症或癫痫的方法，包括向需要的患者施用式(IIa)或(IIb)的化合物的有效量(例如，任何公式((IIa-2)-(IIa-6))的化合物)。本文所描述的化合物(例如，公式(Ia)、(Ib)、(IIa)或(IIb)的化合物)也可用作抗惊厥剂。
• Pyrimidines as novel therapeutic agents
  申请人：Attardo Giorgio

  公开号：US09040538B2

  公开（公告）日：2015-05-26

  The present invention features compounds having the Formula (Ia) and (Ib) (e.g., a compound of any of Formulas ((Ia-2)-(Ia-21)), including other tautomers, stereoisomers, E/Z stereoisomers, prodrugs, pharmaceutically acceptable salts, and compositions thereof. The invention also features methods for treating or preventing pain (e.g., neuropathic pain), inflammation, or epilepsy in a patient by administering an effective amount of a compound of Formula (Ia) or (Ib). The invention also features a method for treating or preventing pain (e.g., neuropathic pain), inflammation, or epilepsy in a patient that includes administering to a patient in need thereof an effective amount of a compound of Formula (IIa) or (IIb) (e.g., a compound of any of Formulas ((IIa-2)-(IIa-6)). The compounds described herein (e.g., a compound of Formulas (Ia), (Ib), (IIa), or (IIb)) can also be used as anticonvulsants.

  本发明涉及具有公式(Ia)和(Ib)的化合物（例如，任何公式((Ia-2)-(Ia-21))的化合物，包括其他互变异构体、立体异构体、E/Z立体异构体、前药、药学上可接受的盐和组合物）。本发明还涉及通过给予公式(Ia)或(Ib)的化合物的有效量来治疗或预防患者的疼痛（例如，神经痛）、炎症或癫痫的方法。本发明还涉及一种治疗或预防患者的疼痛（例如，神经痛）、炎症或癫痫的方法，包括向需要的患者给予公式(IIa)或(IIb)的化合物的有效量（例如，任何公式((IIa-2)-(IIa-6))的化合物）。本文描述的化合物（例如，公式(Ia)、(Ib)、(IIa)或(IIb)的化合物）也可用作抗癫痫药。
• Potential anti-tumor agents XVI. Imidazo[2,1-b]thiazoles
  作者：A ANDREANI、M RAMBALDI、F ANDREANI、R BOSSA、I GALATULAS

  DOI：10.1016/0223-5234(88)90214-0

  日期：1988.7
• Effects of new ubiquinone-imidazo[2,1-b]thiazoles on mitochondrial complex I (NADH-ubiquinone reductase) and on mitochondrial permeability transition pore
  作者：Aldo Andreani、Massimiliano Granaiola、Alberto Leoni、Alessandra Locatelli、Rita Morigi、Mirella Rambaldi、Maurizio Recanatini、Giorgio Lenaz、Romana Fato、Christian Bergamini

  DOI：10.1016/j.bmc.2004.08.012

  日期：2004.11

  In this work we describe the synthesis of a series of imidazo[2,1-b]thiazoles and 2,3-dihydroimidazo[2,1-b]thiazoles connected by means of a methylene bridge to CoQ(0). These compounds were tested as specific inhibitors of the NADH:ubiquinone reductase activity in mitochondrial membranes. The imidazothiazole system when bound to the quinone ring in place of the isoprenoid lateral side chain, may increase the inhibitory effect (with an IC50 for NADH-Q(1) activity ranging between 0.25 and 0.96 muM) whereas the benzoquinone moiety seems to lose the capability to accept electrons from complex I as indicated by very low maximal velocity elicited by the compounds tested. Moreover the low rotenone sensitivity for almost all of these compounds suggests that they are only partially able to interact with the physiological ubiquinone-reduction site. The compounds were investigated for the capability of increasing the permeability transition of the inner mitochondrial membrane in isolated mitochondria. Unlike CoQ(0), which is considered a mitochondrial membrane permeability transition inhibitor, the new compounds were inducers. (C) 2004 Elsevier Ltd. All rights reserved.
• Andreani, Aldo; Rambaldi, Mirella; Carloni, Patricia, Journal of Heterocyclic Chemistry, 1989, vol. 26, p. 525 - 529
  作者：Andreani, Aldo、Rambaldi, Mirella、Carloni, Patricia、Greci, Lucedio、Stipa, Pierluigi

  DOI：——

  日期：——